导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.11% | 1910/4773 |
| 近一周 | -0.05% | 890/5465 |
| 近一月 | 4.91% | 86/5421 |
| 近一季 | 5.75% | 293/5231 |
| 近半年 | 5.39% | 797/4920 |
| 近一年 | 4.20% | 1905/4394 |
| 近两年 | 40.52% | 1878/2954 |
| 近三年 | 49.19% | 570/2253 |
| 成立以来 | 89.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.83% 2927/4961 |
-7.78% 3801/5312 |
- - |
- - |
| 2025 | 10.77% 2788/4813 |
2.58% 1322/3635 |
11.58% 159/4076 |
-8.44% 4037/4524 |
5.70% 408/4813 |
| 2024 | 39.97% 18/3463 |
9.91% 103/2808 |
6.74% 139/3014 |
12.41% 2353/3129 |
6.14% 543/3463 |
| 2023 | -2.35% 576/2656 |
-2.44% 1982/2280 |
1.98% 185/2385 |
4.82% 122/2515 |
-6.37% 1740/2655 |
| 2022 | -4.34% 91/2207 |
2.01% 84/1919 |
-1.26% 1693/2016 |
-7.99% 158/2113 |
3.21% 748/2208 |
| 2021 | 1.14% 690/1822 |
10.50% 35/1255 |
-1.84% 1179/1330 |
-6.23% 907/1466 |
-0.56% 1250/1822 |
| 2020 | 7.06% 870/1250 |
-12.72% 898/1028 |
3.89% 923/1067 |
7.97% 748/1164 |
9.34% 645/1184 |
| 2019 | 28.56% 517/1092 |
16.35% 672/754 |
2.69% 72/804 |
0.28% 536/850 |
7.29% 455/918 |
| 2018 | -11.99% 79/834 |
- - |
- - |
- - |
-9.10% 126/691 |
| 2017 | 16.43% 236/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.75% 111/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证银行指数(LOF)A VS. 长安沪深300非周期A(740101) |